Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Bruker Corporation

Olympus Italia develops customer-oriented solutions for the medical sector. The company has been committed to making people's lives healthier, safer, and more rewarding for over 100 years. Self-described as focused on advancing medical technology.

Olympus Italia

Bruker provides life science and material research solutions, including diagnostics and analytical instruments, self-described as high-value.

Metric
Company Name	Bruker Corporation	Olympus Italia
Symbol	BRKR
MSH ID	COM:BRUKER	IT:OLYMPUS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Medical - Devices	Medical Devices
Country	US	IT
Stage	Post-IPO Equity	Post-IPO Equity
Employee Count	9.71K
Website	bruker.com	olympus.it
LinkedIn		olympus-italy
Founders

Metric
Market Cap	9.27B
Enterprise Value
Monthly Web Traffic	310.13K	132.60K
Web Traffic Growth	0.07	-0.15
Valuation
Raised Capital	403.74M	600M

Metric
Revenue	2.96B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.52B
EBITDA	597.20M
Operating Income	482.30M
Net Income	427.20M
EPS	2.92
Diluted EPS	2.90
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.51
Operating Profit Margin	0.15
EBITDA Margin	0.20
Net Profit Margin	0.14
Return on Equity	0.34
Return on Assets	0.10
Return on Capital Employed	0.14

COM:BRUKER

Bruker

Last Close

56.22

22/11 21:00

Market Cap

9.27B

Beta: -

Volume Today

2.08M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	33.01
P/B Ratio	8.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.35
EV Multiple	20.82

Metric
Days Sales Outstanding	62.86
Days Payables Outstanding	48.37
Days Inventory Outstanding	274.67
Operating Cycle	355.90
Cash Conversion Cycle	304.45
Asset Turnover	0.70

Metric
Operating Cash Flow	350.10M
Free Cash Flow	243.20M
Cash Flow to Debt	0.27
Operating Cash Flow/Sales	0.12
Free Cash Flow Yield	0.02

Metric
Cash & Equivalents	488.30M
Accounts Receivable	-900K
Inventory	968.30M
Goodwill	582.60M
Debt to Capitalization	0.55
Debt to Assets	0.32
Current Ratio	1.89
Quick Ratio	0.93

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.10
SG&A to Revenue	0.18